Navigation Links
Halo Pharmaceutical Welcomes Al Rosenston as its Vice President, Business Development
Date:1/26/2009

WHIPPANY, N.J., Jan. 26 /PRNewswire/ -- Adding to its strong executive team, Halo Pharmaceutical today announced the addition of Allen M. Rosenston, a thirty-five year pharmaceutical industry veteran, as Halo's new Vice President of Business Development. Al comes to Halo from a long and distinguished career at Abbott Laboratories where he held diverse roles in operations, business development, and related business functions. "The addition of Al to the Halo business development team is a significant achievement. Al has deep experience within the pharmaceutical industry. He developed Abbott's domestic Contract Pharmaceutical Manufacturing Business Unit and, at the time of his retirement, he was responsible for the global finished goods contract manufacturing business," according to Mohd Asif, Halo's Chief Financial Officer.

Al comes to Halo shortly after Halo's acquisition of its Whippany, NJ facility, a facility which has been producing various dosage forms for 35 years. "I am thrilled to be part of the Halo Pharmaceutical team, and to build on the legacy of this outstanding facility and group of talented people with an average seniority of over 20 years. Based on my discussions with the new Halo team, this is a unique opportunity to create a world-class pharmaceutical services company right in the heart of New Jersey. Maintaining focus on quality, service, and compliance, along with the flexible manufacturing capabilities of the Whippany facility, will create a high-level of interest with prospective customers. I anticipate us to be highly competitive when overall service value is assessed."

Halo capabilities include an impressive array of formulation services, operations for the aseptic filling of topical ointments, solid dosage forms (tablets and capsules), liquids, suppositories, associated packaging (tablet, powder, liquids and HUD) and ample laboratory space for formulation development, pre-clinical and clinical supplies and support of commercial operations. An additional asset is the site's capability to manufacture controlled substances (C2-C5) and an API manufacturing unit with an outstanding track-record of meeting DEA requirements.

Al joined Halo on January 5, 2009, and can be reached at arosenston@halopharma.com or at 973-428-4087.

About Halo Pharmaceutical

Halo Pharmaceutical, headquartered in Whippany, NJ, is a full-service, specialty pharmaceutical company, offering state-of-the-art contract manufacturing, early stage formulation development and laboratory services to the pharmaceutical and related industries. Halo is currently a supplier of choice to a number of large and medium size brand pharmaceutical companies for important lifecycle products. Contract manufacturing capabilities include the ability to conduct aseptic filling, granulation, blending, tableting, coating, packaging, and related warehousing operations. Halo Pharmaceutical is a privately-held company.


'/>"/>
SOURCE Halo Pharmaceutical
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. KV Pharmaceutical Suspends Product Manufacturing, Shipping
2. KV Pharmaceuticals Launch of Gestiva(TM) Delayed
3. Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
4. Caraco Pharmaceutical Laboratories, Ltd. to Announce Third Quarter of Fiscal Year 2009 Results on January 29, 2009
5. University Medical Pharmaceuticals Appoints Tom Roche as Senior Vice President, Global Sales and Marketing
6. Amylin Pharmaceuticals to Webcast Year-End Results
7. Renhuang Pharmaceuticals, Inc. Engages New Independent Auditor
8. Abbott Opens New Pharmaceutical Research Laboratory in Singapore
9. Law Firm Freedland Russo Spearheads Record-Setting Whistleblower Case Against Pharmaceutical Giant Eli Lilly -- Firm Expands Offices to Include L.A. Entertainment Branch
10. NUCRYST Pharmaceuticals appoints a new director
11. Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Pepper Flow promotional review platform at the Promotional Review Committee Compliance and ... help marketers streamline the medical, legal, and regulatory review (MLR) process – ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: ... Consulting, LLC , and named its founder as Diplomat,s ... Tennessee , will operate under Diplomat ... service offerings for health care partners to include IT ... "In an interoperable world, technology delivers comprehensive ...
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
Breaking Medicine Technology: